Protalix BioTherapeutics posts corporate presentation outlining rare-disease portfolio, PRX-115 development plans

Protalix Biotherapeutics, Inc.

Protalix Biotherapeutics, Inc.

PLX

0.00
  • Protalix BioTherapeutics highlighted European Commission clearance for an Elfabrio 2 mg/kg every-4-weeks dosing option in stable adult Fabry patients, positioning it as only EU enzyme replacement therapy with a monthly regimen.
  • Chiesi milestone payment tied to dosing update totaled USD 25 million, contributing to USD 33.8 million revenue in Q1 2026.
  • Cash and cash equivalents stood at USD 51.1 million as of March 31, 2026; company reported no debt and no warrants.
  • PRX-115 Phase 2 RELEASE study in uncontrolled gout is enrolling; top-line data targeted for 2H 2027 with dosing arms designed to test every-4-weeks use without methotrexate.
  • Common stock outstanding listed at 80,500,000 shares as of May 1, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.